Abstract
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with especially higher morbidity in Asian population.Currently, IgAN is one of the important causes for end-stage renal disease, with clinical features including hematuria, proteinuria, and hypertension. The major pathological characteristics of IgAN are IgA deposits in the glomerular mesangium, mesangial cell proliferation, and capillary endothelial cell proliferation. Elevated circulating levels of galactose-deficient IgA1 (Gd-IgA1), increased production of immune complexes of Gd-IgA1, and deposition of these complexes in glomerular mesangium are the widely accepted mechanism of IgAN. Kidney biopsy remains the only definitive method for diagnosing IgAN. Current treatments for IgAN are based on renin-angiotensin system blockade and management of blood pressure, the combination of which with appropriate immunosuppressants, cytotoxic drugs, and fish oil might be able to delay the progression of IgAN. The purpose of present review was to summarize the progress of research on diagnosis and treatment for IgAN to provide data and guidance for further clinical work and scientific research. Key words: IgA nephropathy; Mechanism; Treatment
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
